StackItSmart

Compound reference

GHRP-6

Peptides2 cited findingsClinical review: not reviewed

Safety findings

Regulatory recordSupporting passage inspected

FDA describes limited GHRP-6 safety information and concerns about possible cortisol effects and increased glucose associated with reduced insulin sensitivity. This is a regulator’s assessment of limited evidence, not a quantified event rate.[1]

  • The inspected FDA summary does not establish the frequency or severity of these effects for a particular preparation or user.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

· Independent fresh reinspection for the deep-evidence pass: reopened every cited source at its passages via NCBI E-utilities / DailyMed / accessdata.fda.gov / govinfo.gov / Wayback Machine mirror, checked Europe PMC correction/retraction metadata where applicable, and confirmed the claim's wording against the primary text. Disposition: supported within the stated scope. No qualified clinical review.

Interaction evidence

Human observational studySupporting passage inspected

A small retrospective study of men already receiving testosterone found increased IGF-1 with combined sermorelin, GHRP-2 and GHRP-6. Seven of the 14 men were also taking an aromatase inhibitor or tamoxifen, and the paper reports that blocking estrogen action reduced the IGF-1 rise. Glucose and insulin tolerance were not measured, so this study cannot establish the metabolic harm or safety of any two secretagogues.[2]

  • Three peptides, testosterone and, in half the cohort, an aromatase inhibitor or tamoxifen were used together; no pair-specific or long-term safety conclusion.
  • Glucose and insulin tolerance were explicitly not evaluated in this study.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Supporting passages inspected, scope corrected and legacy assertions reassessed; no clinician review performed.

· Independently re-obtained the full text on 2026-09-09 via PMC BioC after the original SAGE URL returned HTTP 403 on retry; identified and added the aromatase-inhibitor/tamoxifen confound in 7 of 14 men, which the prior wording did not mention.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Recorded FDA’s limited-information assessment and potential cortisol/glucose concerns without inventing frequency or severity.

  • A direct clinical source is still needed for precise effects, pharmacokinetics and clinical outcomes.
  • Other inherited assertions not supported by the published claim set remain unverified; no qualified clinician review has occurred.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. FDA: Certain bulk drug substances for compounding that may present significant safety risks

    US Food and Drug Administration. FDA web page. The footer states "Content current as of: 04/22/2026" (22 April 2026), independently verified on 2026-09-09 by two separate fetch methods. The ibutamoren mesylate row's own dated actions remain the applicable dates for that row's content. 2026-04-22. Regulatory document.

    Inspected location: Ibutamoren mesylate row of the 503A/503B category-2 bulk-substances table: congestive-heart-failure safety-risk description and the row's own dated entries (503A added September 29, 2023; 503B added December 29, 2022). Also inspected for this batch: the category-2 table row for kisspeptin-10, and the withdrawn-nomination rows for BPC-157, cathelicidin LL-37, emideltide (DSIP), epitalon, GHK-Cu, melanotan II, MOTs-C, selank acetate (TP-7), semax (heptapeptide) and thymosin alpha-1; and the earlier named GHRP-6, PEG-MGF, GHK-Cu and GHRP-2 rows

    Study context and inspection record
  2. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels

    2017. DOI:10.1177/1557988317718662 · PMCID:PMC5675260 · PMID:28830317 Full text inspected.

    Inspected location: Abstract; Methods Patient Cohort (105 screened, 14 met inclusion, 3+4 also on an aromatase inhibitor and/or tamoxifen); Results and Table 2; Discussion limitations on unmeasured insulin tolerance/fasting glucose and prospective design

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • peptide-fda-bulk-safety: Named rows: GHRP-6, PEG-MGF, GHK-Cu, GHRP-2 and ibutamoren; current and withdrawn-nomination tables
  • Inspected compound-specific FDA table passage; a primary clinical report was not retrieved for quantitative validation.

View this compound in the research library →

Related records in this class

Grouped under Peptides for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.